Difference between revisions of "Section 7: Treatments for SARS-CoV-2 Infection (from DOI: 10.1007/s11886-020-01292-3) (Q10740)"
Jump to navigation
Jump to search
(Created claim: named entity (P78): eculizumab (chemical - MeSH supplementary concept) (Q10955), #quickstatements; #temporary_batch_1592945455790) |
(Created claim: named entity (P78): Adalimumab (chemical - MeSH descriptor) (Q10969), #quickstatements; #temporary_batch_1592945455790) |
||
| Property / named entity | |||
| + | |||
| Property / named entity: Adalimumab (chemical - MeSH descriptor) / rank | |||
| + | Normal rank | ||
Revision as of 20:51, 23 June 2020
Publication: "Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response"published as Curr Cardiol Rep; 2020 04 21 ; 22 (5) 32; DOI: 10.1007/s11886-020-01292-3
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Section 7: Treatments for SARS-CoV-2 Infection (from DOI: 10.1007/s11886-020-01292-3)
|
Publication: "Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response"published as Curr Cardiol Rep; 2020 04 21 ; 22 (5) 32; DOI: 10.1007/s11886-020-01292-3
|
Statements
Q10356 (Deleted Item)
0 references
Q10356 (Deleted Item)
0 references
0 references
0 references
0 references
